FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
Clinical trial NCT07012798 · RECRUITING
Trial details
- NCT number
- NCT07012798
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-25
- Primary completion
- 2026-06-30
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.